TY - JOUR
T1 - A significant association of non-obese non-alcoholic fatty liver disease with osteosarcopenic obesity in females 50 years and older
AU - Kashiwagi, Kazuhiro
AU - Takayama, Michiyo
AU - Ichikawa, Hitoshi
AU - Takaishi, Hiromasa
AU - Iwao, Yasushi
AU - Kanai, Takanori
N1 - Publisher Copyright:
© 2021 European Society for Clinical Nutrition and Metabolism
PY - 2021/4
Y1 - 2021/4
N2 - Background & aims: Osteosarcopenic obesity (OSO) encompassing obesity, sarcopenia and osteopenia, is due to redistribution or infiltration of fat into muscle and bone. This cross-sectional study evaluated the association between OSO and non-alcoholic fatty liver disease (NAFLD). Methods: Obesity, sarcopenia and osteopenia was defined using the percentage of body fat mass, reduced muscle mass, and the percentage of young adult mean < 80%, measured by dual-energy x-ray absorptiometry, respectively. Non-obese and obese NAFLD was diagnosed by ultrasound and body mass index cut-off point (25 kg/m2). A total of 619 subjects ≥ 50 years who completed health checkups were divided into obesity group including OSO and sarcopenic obesity (SO) alone phenotype, and non-obesity group that did not belong to any phenotype, including standard (St). Results: Overall osteopenia and OSO were detected in only 10% and 1% in males, compared with 45% and 9% in females, respectively. Multivariate analysis for females demonstrated a significant association of OSO with non-obese NAFLD (odds ratio = 3.737, 95% confidence interval = 1.365–10.233, P = 0.010), while the association between SO alone and non-obese NAFLD was equivocal. The OSO phenotype had a significantly higher proportion of slower walking speed and weaker grip strength, compared to the St phenotype. The proportion of OSO increased with age in contrast to constant prevalence of non-obese NAFLD. Conclusion: Non-obese NAFLD had a significant association with OSO in females, independent of plausible confounders. These results suggest that non-obese NAFLD might be an independent risk factor for OSO.
AB - Background & aims: Osteosarcopenic obesity (OSO) encompassing obesity, sarcopenia and osteopenia, is due to redistribution or infiltration of fat into muscle and bone. This cross-sectional study evaluated the association between OSO and non-alcoholic fatty liver disease (NAFLD). Methods: Obesity, sarcopenia and osteopenia was defined using the percentage of body fat mass, reduced muscle mass, and the percentage of young adult mean < 80%, measured by dual-energy x-ray absorptiometry, respectively. Non-obese and obese NAFLD was diagnosed by ultrasound and body mass index cut-off point (25 kg/m2). A total of 619 subjects ≥ 50 years who completed health checkups were divided into obesity group including OSO and sarcopenic obesity (SO) alone phenotype, and non-obesity group that did not belong to any phenotype, including standard (St). Results: Overall osteopenia and OSO were detected in only 10% and 1% in males, compared with 45% and 9% in females, respectively. Multivariate analysis for females demonstrated a significant association of OSO with non-obese NAFLD (odds ratio = 3.737, 95% confidence interval = 1.365–10.233, P = 0.010), while the association between SO alone and non-obese NAFLD was equivocal. The OSO phenotype had a significantly higher proportion of slower walking speed and weaker grip strength, compared to the St phenotype. The proportion of OSO increased with age in contrast to constant prevalence of non-obese NAFLD. Conclusion: Non-obese NAFLD had a significant association with OSO in females, independent of plausible confounders. These results suggest that non-obese NAFLD might be an independent risk factor for OSO.
KW - Non-obese non-alcoholic fatty liver disease
KW - Osteosarcopenic obesity
KW - Sarcopenic obesity
UR - http://www.scopus.com/inward/record.url?scp=85101146606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101146606&partnerID=8YFLogxK
U2 - 10.1016/j.clnesp.2021.01.045
DO - 10.1016/j.clnesp.2021.01.045
M3 - Article
C2 - 33745573
AN - SCOPUS:85101146606
SN - 2405-4577
VL - 42
SP - 166
EP - 172
JO - Clinical Nutrition ESPEN
JF - Clinical Nutrition ESPEN
ER -